DE-CSC
9.10.2019 14:02:11 CEST | Business Wire | Press release
CSC announces a new domain name security intelligence API that can now bring together the power of CSC’s domain name security intelligence with other cloud-based security operations platforms. Debuting today at the FireEye Cyber Defense Summit 2019, this new solution will help the world's leading security experts, government leaders, and executives from various industries address important challenges in today’s cyber threat landscape, including the vulnerability of digital assets like domains, domain name systems (DNS), and digital certificates outside the firewall, noted by both companies as serious security blind spots.
Cyber threats such as domain name and DNS hijacking events enable criminals to redirect web traffic, email, apps, and other connections to services that rely on the hijacked domain name. The exploitation of weaknesses in DNS infrastructure is caused by a lack of controls, processes, and policies with most organizations. For clients leveraging a security operations platform or a SIEM, it’s now possible to display all your security intelligence in one place, adding security controls for domains, DNS, and digital certificates. This insight can help organizations mitigate the disruption of business continuity, leading to financial repercussions, loss of consumer trust, and sensitive data leaks. This is the first time any organization is able to integrate security controls for digital assets outside the firewall into their security operations platform including a SIEM.
“Customers today have vendor fatigue and are overwhelmed by managing multiple, disparate security solutions. With the CSC API accessible, our mutual customers will be able to monitor a suite of security events that occur outside their company’s firewall when integrated with the FireEye Helix Security Platform,” says Sean Morton, vice president of Customer Experience at FireEye. “Detecting risks such as DNS and domain name hijacking removes a significant blind spot in a company’s security strategy, providing valuable intelligence and alerts inside our security operations platform, ultimately increasing the efficiency and incident response times dealing with cyber threats.”
“As the world’s leading corporate domain name registrar, CSC is the only company in the unique position to provide visibility into the cyber risks associated with your business-critical digital assets outside the firewall—domains, DNS, and digital certificates. Coupled with other security operations platforms like FireEye Helix, our joint customers have access to a next generation security platform,” says Mark Calandra, senior vice president, CSC Digital Brand Services. “In response to the risk of DNS hijacking and other cyber crime noted in the Department of Homeland Security’s emergency directive and the UK National Cyber Security Centre’s security advisory , CSC’s advanced proprietary algorithms are designed to expose these blind spots that are a critical component for enhancing the security posture of any company with an online presence.”
The Cyber Defense Summit is being hosted by FireEye, and the conference takes place October 9-10, 2019, in Washington, D.C. CSC representatives will be in the exhibition hall to discuss CSC’s new Domain Name Security Intelligence API and its integration with FireEye Helix. We will also be discussing our recent Cyber Security Report highlighting the domain name security posture of global government defense contractors.
About CSC
CSC supports companies that are making significant investments in their security posture by exposing blind spots that exist within fundamental internet assets such as domain names, DNS, and digital certificates. By leveraging our proprietary security solutions, CSC secures companies from cyber threats to their digital assets, helping them avoid devastating revenue loss, brand reputation damage, or significant financial penalties as a result of policies like GDPR. Along with internet assets, CSC protects online brands that are being exploited via counterfeit websites, fraud, and IP violations, and helps monitor and mitigate this, providing enforcement and advisory services to protect many of the world’s largest brands. Learn more at cscdigitalbrand.services .
About FireEye, Inc.
FireEye is the intelligence-led security company. Working as a seamless, scalable extension of customer security operations, FireEye offers a single platform that blends innovative security technologies, nation-state grade threat intelligence, and world-renowned Mandiant® consulting. With this approach, FireEye eliminates the complexity and burden of cyber security for organizations struggling to prepare for, prevent, and respond to cyber-attacks. FireEye has over 8,200 customers across 103 countries, including more than 50 percent of the Forbes Global 2000.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191009005016/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
